Skip to content

Clinical Study of the Yishen Tiaogan Formula for Improving Bone Metastases of Breast Cancer

Clinical Study of the Yishen Tiaogan Formula for Improving Bone Metastases of Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118346
Enrollment
Unknown
Registered
2026-02-04
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastasis of breast cancer

Interventions

Treatment group:The subjects were intervened with the postoperative formula for breast cancer and the formula for nourishing the kidney and regulating the liver. The ingredients of the kidney-Nourishi
Control group:Postoperative formula for breast cancer: Raw Astragalus membranaceus 15g, Codonopsis pilosula 12g, stir-fried Atractylodes macrocephala 9g, Poria cocos 12g, Astragalus umbellatus 30g, Co

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 and <=75 2. Diagnosed with breast cancer and concomitant bone metastases from breast cancer 3. TCM syndrome pattern consistent with "liver and kidney deficiency" 4. ECOG performance status = 3 5. Willing to accept the treatment protocol of this study

Exclusion criteria

Exclusion criteria: 1. Those with severe cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, or hematological disorders. 2. Those with a history of other tumors. 3. Those with mental disorders who cannot cooperate with the trial. 4. Those who have participated in other clinical trials within the past three months.

Design outcomes

Primary

MeasureTime frame
Objective response rate;

Secondary

MeasureTime frame
Disease control rate;Bone metabolism markers (osteocalcin, 25-hydroxyvitamin D, ß-collagen specific sequence, total type I collagen amino-terminal extension peptide determination);Bone density test;Expression of SOCS3 in peripheral blood and methylation level of SOCS3;Serum alkaline phosphatase (ALP) in peripheral blood, albumin-to-alkaline phosphatase ratio (AAPR), red cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR) in peripheral blood, and carbohydrate antigen 15-3 (CA15-3);Traditional Chinese Medicine symptom and sign scoring;Pain assessment;Quality of Life Assessment;

Countries

China

Contacts

Public ContactChen Hongfeng

Longhua Hospital Shanghai University of Traditional Chinese Medicine

17864190466@163.com+86 189 1776 3058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026